Abstract: Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.
Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
Type:
Application
Filed:
June 28, 2019
Publication date:
October 17, 2019
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Shinji SATO, Kenji MAEDA, Dai ISHIKAWA, Mai NAKAMURA
Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.
Type:
Application
Filed:
July 28, 2017
Publication date:
October 17, 2019
Inventors:
Lei LIANG, Yongkai CHEN, Liu HU, Wei FENG, Chaodong WANG
Abstract: In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.
Type:
Application
Filed:
March 15, 2019
Publication date:
October 17, 2019
Inventors:
Brian Lannutti, Todd Covey, Allard Kaptein, Dave Johnson, Jay Stamatis, Cecile M. Krejsa, John Gregory Slatter
Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.
Abstract: This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
Abstract: The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.
Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.
Type:
Application
Filed:
March 1, 2019
Publication date:
October 17, 2019
Applicant:
Alios BioPharma, Inc.
Inventors:
Robert Than HENDRICKS, Leonid BEIGELMAN, David Bernard SMITH, Antitsa Dimitrova STOYCHEVA
Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
Type:
Application
Filed:
July 13, 2017
Publication date:
October 17, 2019
Applicants:
The Children's Medical Center Corporation, Dana-Faber Cancer Institute, Inc.
Inventors:
James BRADNER, Jun QI, Dennis BUCKLEY, Leonard I. ZON, Elizabeth MACARI
Abstract: Compositions for inhibiting the aggregation of a granin from a non-toxic low molecular weight form to a toxic high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form are provided. Such a composition typically includes one or more active compounds or agents, which may also be referred to herein as disaggregation compounds. Using the compounds and compositions described herein, methods of i) modulating, inhibiting or preventing the interaction of granins with metal ions, ii) modulating, inhibiting, preventing the aggregation of granins or dissociating aggregated granins, iii) reducing or inhibiting cell toxicity, iv) treating or preventing dementia or Alzheimer's disease, and v) preventing or treating Parkinson's and/or Huntington's diseases are also provided.
Abstract: The present disclosure relates to a method for inhibiting Fatty Acid Synthase (FASN) with a FASN inhibitor, methods for treating cancer and viral infections with a FASN inhibitor, and compounds and compositions inhibiting FASN.
Type:
Application
Filed:
April 20, 2017
Publication date:
October 17, 2019
Inventors:
Jesse Kwiek, Timothy Haystaad, Philip Hughes, Yazan Aiwarawrah
Abstract: The disclosure relates to compounds and compositions that inhibit NF-?B and are useful in the treatment of hematological malignancies such as lymphoma and myeloma.
Type:
Application
Filed:
June 26, 2019
Publication date:
October 17, 2019
Inventors:
Johannes ZAKRZEWSKI, Hsiou-Chi LIOU, Samedy OUK
Abstract: Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.
Type:
Application
Filed:
June 28, 2019
Publication date:
October 17, 2019
Applicant:
The Trustees of the University of Pennsylvania
Abstract: The present disclosure relates to methods of using cannabinoid CB2 receptor agonist compositions to suppress pain (e.g., neuropathic pain), opioid tolerance, and/or opioid-induced physical dependence in a subject.
Type:
Application
Filed:
January 24, 2019
Publication date:
October 17, 2019
Applicant:
Indiana University Research and Technology Corporation
Inventors:
Andrea Grace HOHMANN, Ken Paul MACKIE, Xiaoyan LIN, Amey S. DHOPESHWARKAR
Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
Type:
Application
Filed:
May 21, 2019
Publication date:
October 17, 2019
Inventors:
Brunangelo Falini, Maria Paola Martelli
Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.
Type:
Application
Filed:
May 24, 2019
Publication date:
October 17, 2019
Inventors:
Manchi CM Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
Abstract: The present invention relates to the use of compounds or pharmaceutical compositions comprising the same, and methods of treatment using the same, in the prophylaxis and/or treatment of alopecia areata, vitiligo, cutaneous lupus, lupus nephritis, giant cell arteritis, sarcoïdosis and/or sarcoïdosis-related conditions. In particular the compounds are JAK inhibitors.
Type:
Application
Filed:
November 9, 2017
Publication date:
October 17, 2019
Inventors:
Chantal Thérèse TASSET, Pille HARRISON, René Alexandre GALIEN, John Sargent SUNDY, John G. MCHUTCHISON, Thomas O'RIORDAN, Neelufar MOZAFFARIAN, Uptal Dinesh PATEL, Timothy R. WATKINS, David L. GOSSAGE
Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, a calcium channel blocker, and a beta-blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.
Abstract: Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
Abstract: Provided herein is a process for the preparation of Chlorpromazine or its pharmaceutically acceptable salts, preferably process for the preparation of Chlorpromazine or its pharmaceutically acceptable salts thereof having high purity.
Abstract: Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
Type:
Application
Filed:
January 9, 2019
Publication date:
October 17, 2019
Inventors:
Brian A. Bernick, Peter H.R. Persicaner, Julia M. Amadio
Abstract: Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method may comprise the step of administering a composition comprising obeticholic acid to an individual in need thereof.
Abstract: The present invention provides a lipolysis composition comprising deoxycholic acid or pharmaceutically acceptable salts thereof and a pharmaceutical composition for preventing or treating obesity, comprising, for example, topical obesity. The pharmaceutical composition of the present invention does not cause a precipitate even at a low pH compared to a conventional DCA-containing preparation, thus not only showing excellent storage stability, but also minimizing side effects such as a burning sensation, inflammations, etc. in a site of administration.
Type:
Application
Filed:
April 15, 2019
Publication date:
October 17, 2019
Inventors:
Dongkyu Park, Sang Yun Lee, Young Sub Song, Surin Kim, Seung Jun Lee, Hana Lee, Seung Ho Ji
Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.
Type:
Application
Filed:
June 25, 2019
Publication date:
October 17, 2019
Applicant:
REGENERA PHARMA LTD.
Inventors:
Zadik HAZAN, Konstantin ADAMSKY, Andre C. B. LUCASSEN, Nurit NOVAK
Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
Abstract: The present invention relates, inter alia, to methods for the prevention or treatment of cancer, and to compositions, combinations and kits for the treatment or prevention of cancer. In one embodiment, the invention provides a method of treating or preventing cancer, comprising administering to a patient in need thereof an immune checkpoint modulator together with a compound of Formula (I): wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation; and wherein at least 70% of the X groups is SO3M.
Abstract: Described herein are nanoparticle-based compositions, kits, methods and platforms for delivering drugs to professional APCs (PAPCs) in vivo resulting in a robust and specific immune response to a pathogen, e.g., Leishmania major. The composition, kits, platforms and methods involve the combined use of MHC targeting and immunogenic moieties (e.g., PADRE) with dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of anti-pathogen agents (e.g., AmB) to PAPCs via MHC class II molecules expressed on the surface of such cells such that the anti-pathogen agent is internalized by the PAPCs. The composition, kits, platforms and methods described herein provide for specific and efficient delivery of anti-pathogen agents (e.g., drugs such as AmBisome®) to PAPCs in vivo that results in a reduction of growth or elimination of the pathogen involving a robust and specific immune response to the pathogen.
Type:
Application
Filed:
April 16, 2019
Publication date:
October 17, 2019
Inventors:
Pirouz M. Daftarian, Victor Perez, Arba Leroy Ager
Abstract: The invention relates to modulation of SIRT3 activity levels. The invention has applications for regulating metabolism and mimicking caloric restriction or exercise in a muscle cell.
Type:
Application
Filed:
June 27, 2018
Publication date:
October 17, 2019
Applicant:
President and Fellows of Harvard College
Abstract: A first aspect of the invention relates to a method of treating AML in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.
Abstract: The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.
Abstract: The present invention provides vectors for delivering to a cell, or expressing in a cell, a therapeutic RNA that is capable of reducing expression of a target gene. Compositions comprising the vectors and comprising the therapeutic RNAs are also provided, as are methods for their use.
Abstract: Provided herein are methods for the prevention and treatment of an abnormal tissue condition in the liver (e.g., liver cancer) of a subject, based on the administration of an inhibitor of a G protein-coupled estrogen receptor 1 (GPER1).
Abstract: PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.
Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
Type:
Application
Filed:
June 14, 2019
Publication date:
October 17, 2019
Inventors:
MARKUS HOSSBACH, MONIKA KRAMPERT, HANS-LOTHAR ARTH
Abstract: The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
Type:
Application
Filed:
September 18, 2018
Publication date:
October 17, 2019
Applicant:
ALFASIGMA S.P.A.
Inventors:
Paola Maffei, Marco Mascagni, Giuseppe Claudio Viscomi
Abstract: The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid.
Abstract: A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.
Abstract: An article of apparel including a delivery layer and a component releasable from the layer is disclosed. In an embodiment, the apparel includes a textile base layer the delivery layer oriented to contact the skin of the wearer. The delivery layer is formed from a composition including the releasable component. In another embodiment, the textile is formed of strands coated with the releasable component. In still further embodiments, the strands are formed of the releasable component. The apparel may release the component to the skin of the wearer.
Abstract: A transdermal magnesium cream composition and related method of creating the formulation includes: magnesium chloride, water, hydroxypropyl starch phosphate, at least one emulsifier selected from cetearyl olivate or sorbitan olivate, isopropyl palmitate, emulsifying wax, cetyl alcohol, glycerin, butyrospermum parkii (shea butter). The composition also includes at least one preservative selected from iodopropynyl butylcarbamate, phenoxyethanol, caprylyl glycol, benzyl alcohol, benzoic acid, or sorbic acid.
Abstract: Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells, such as those that have been genetically modified, for instance, to express a heterologous transgene. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be genetically modified, for example, to express transgenes encoding therapeutic proteins. Genetically modified hematopoietic stem and progenitor cells may be expanded, for instance, by treatment ex vivo with an aryl hydrocarbon receptor antagonist, and may be infused into a patient, such as a patient in need of hematopoietic stem cell transplant therapy. Thus, provided herein are methods for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.
Type:
Application
Filed:
October 31, 2018
Publication date:
October 17, 2019
Inventors:
Anthony BOITANO, Michael COOKE, Kevin A. GONCALVES
Abstract: A method of decreasing IL-6 level in a subject, comprising: identifying a subject in need thereof; and administering to the subject a composition that contains small cells that are greater than 2 micrometer s and less than 6 micrometer s in size; wherein the small cells include somatic stem cells that are (i) pluripotent; and (i) CD349(+), CD9(?), Oct4(+), Nanog(?), Lgr5(+), CD66e(+), CD133(+), or CD34(+).
Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.
Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.
Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Application
Filed:
June 7, 2019
Publication date:
October 17, 2019
Inventors:
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Application
Filed:
June 7, 2019
Publication date:
October 17, 2019
Inventors:
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Type:
Application
Filed:
June 26, 2019
Publication date:
October 17, 2019
Inventors:
Roshantha A. Chandraratna, Martin E. Sanders